Addex Highlights Strength of Allosteric Modulation Technology Platform with Multiple Presentations at Society for Neuroscience 2010
(Thomson Reuters ONE) -
Addex Pharmaceuticals /
Addex Highlights Strength of Allosteric Modulation Technology Platform with
Multiple Presentations at Society for Neuroscience 2010
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 12 November 2010 - Allosteric modulation company Addex
Pharmaceuticals (SIX:ADXN) announced today that data on a total of nine
therapeutic programs will be presented during Society for Neuroscience 2010
(November 13-17, San Diego, USA), highlighting the strength of its allosteric
modulation technology platform. The data being presented cover multiple receptor
types and therapeutic areas, including Parkinson's disease, schizophrenia,
anxiety, Alzheimer's disease and depression.
"The data generated by Addex and our partners, Ortho-McNeil-Janssen and Merck &
Co., being presented at the Society for Neuroscience 2010 conference illustrate
the power of our allosteric modulation product generating engine. Although the
targets we are addressing have been pursued for many years with standard
discovery technologies, most have proven elusive," explained Dr. Vincent Mutel,
CEO of Addex. "Our technology is allowing us to bring a new kind of chemistry to
industrial drug discovery efforts and thereby improve discovery productivity, a
key bottleneck hindering the pharmaceutical industry. Beyond our presentations
at Society for Neuroscience this year, we have recently demonstrated our ability
to expand our discovery technology beyond GPCRs, like glutamate receptors, to
cover other types of cell surface receptors, such as cytokine receptors,
including TNF receptors. In addition to advancing our own molecules, we will
look to sign multiple collaborative partnerships to realize the potential of our
platform."
Small molecule allosteric modulators represent an unexploited kind of chemistry
which is different from the traditional small molecule drugs. Orally available
allosteric modulators can offer multiple competitive advantages over classical
drugs. Most importantly, they can be more specific for their target receptor in
the body, while at the same time, offering more precise control over receptor
function. They can do this because they bind to cell surface receptors at a
different site than traditional drugs. Although allosteric binding sites offer
greater control, molecules that bind them cannot be identified using
conventional high throughput screening techniques.
Society for Neuroscience 2010 Presentations
Sun, Nov 14, 8:00 - 9:00 AM
162.9/V17 - Novel triazinedione derivatives as GABAB receptor positive
allosteric modulators: Synthesis, in vitro pharmacological characterization,
pharmacokinetic profile and in vivo activity in rodent model of anxiety
Mon, Nov 15, 8:00 - 9:00 AM
406.9/MMM57 - An mGluR2/3 negative allosteric modulator improves recognition
memory assessed by natural forgetting in the novel object recognition test in
the rat
Mon, Nov 15, 2:00 - 3:00 PM
514.14/OOO34 - Validating the role of mGluR4 receptors in the physiopathology of
anxiety using a selective mGluR4 positive allosteric modulator
Tue, Nov 16, 11:00 AM - 12:00 PM
557.12/M18 - Anti-parkinsonian and anti-dyskinetic effects of ADX48621, a novel
mGlu5 negative allosteric modulator
Tue, Nov 16, 1:00 - 2:00 PM
642.5/E29 - JNJ-40068782: A novel potent, selective and systemically active
positive allosteric modulator of the mGlu2 receptor
Tue, Nov 16, 2:00 - 3:00 PM
643.22/F23 - Identification and characterization of radioligands that bind to an
allosteric modulator site on the mGlur4 receptor
Tue, Nov 16, 3:00 - 4:00 PM
651.15/I6 - Selective mGluR2 negative allosteric modulators reverse the
scopolamine-induced deficit in the novel object recognition test
Wed, Nov 17, 2:00 - 3:00 PM
886.14/VV7 - Effects of a mGluR2/3 negative allosteric modulator and a reference
mGluR2/3 orthosteric antagonist in a genetic mouse model of depression
Wed, Nov 17, 3:00 - 4:00 PM
885.11/TT19 - Development of a cAMP BRET cellular HTS assay to characterize
pharmacological properties of mGluR7 ligands
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric
modulators for human health. The company is focused on using its proprietary
discovery platform to target cell surface receptors that are well recognized as
having therapeutic potential for treating diseases of the central nervous
system, metabolic disorders or inflammation. Subject to regulatory approvals,
several Phase II clinical trials are expected to start soon for two lead
products: ADX48621 and ADX71149. ADX48621 is an mGluR5 negative allosteric
modulator (NAM), which will be tested in Parkinson's disease levodopa-induced
dyskinesia (PD-LID) and, separately, non-Parkinsonian patients suffering from
dystonia, a movement disorder also observed in PD. ADX71149 is an mGluR2
positive allosteric modulator (PAM), which has potential for treatment of
schizophrenia, anxiety and other indications. ADX71149 is licensed to Ortho-
McNeil-Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. Other
products nearing the clinic include: ADX71943, a GABA-B receptor PAM with
potential for chronic pain; and ADX68692, a follicle stimulating hormone
receptor (FSHR) NAM, with potential for endometriosis and benign prostatic
hyperplasia; and, mGluR2 NAM for Alzheimer's disease. In addition, Merck & Co.,
Inc. has licensed rights to two preclinical programs: mGluR4 PAM for Parkinson's
disease and mGluR5 PAM for schizophrenia. Preclinical discovery stage programs
include: GLP1R PAM; IL1R1 NAM; and TNFR1 NAM.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
[HUG#1462229]
--- End of Message ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland
ISIN: CH0029850754;
Deutsch (pdf):
http://hugin.info/138017/R/1462229/401179.pdf
Français (pdf):
http://hugin.info/138017/R/1462229/401178.pdf
English (pdf):
http://hugin.info/138017/R/1462229/401177.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 12.11.2010 - 18:01 Uhr
Sprache: Deutsch
News-ID 48746
Anzahl Zeichen: 10523
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex Highlights Strength of Allosteric Modulation Technology Platform with Multiple Presentations at Society for Neuroscience 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
